key: cord-1026839-znpl96yy authors: Roth, Nicole; Schön, Jacob; Hoffmann, Donata; Thran, Moritz; Thess, Andreas; Mueller, Stefan O.; Petsch, Benjamin; Rauch, Susanne title: CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats date: 2021-05-13 journal: bioRxiv DOI: 10.1101/2021.05.13.443734 sha: f165443b53b1c6e8af772f45793d0ff9665a901d doc_id: 1026839 cord_uid: znpl96yy More than a year after emergence of the SARS-CoV-2 pandemic, multiple first-generation vaccines are approved and available for vaccination. Still, many challenges remain. The ongoing vaccination programs across the globe suffer from insufficient vaccine supply. The virus is adapting to the human host and novel variants are circulating that are neutralised less efficiently by antibodies raised against ancestral SARS-CoV-2 variants. Here, we describe CV2CoV, a second-generation mRNA vaccine developed for enhanced protein expression and immunogenicity. CV2CoV supports increased levels of protein expression in cell culture compared to our clinical candidate CVnCoV. Vaccination with CV2CoV induces high levels of virus neutralising antibodies with accelerated kinetics in rats. Robust antibody responses are reflected in significant cross-neutralisation of circulating SARS-CoV-2 variants of concern, i.e. B.1.1.7 and B.1.351. Together, these results underline the value of CV2CoV as next-generation SARS-CoV-2 mRNA vaccine. The ongoing COVID19 pandemic creates a worldwide need for fast development of vaccines. By April 2021, thirteen vaccines against SARS-CoV-2 have received authorisation by at least one national regulatory authority 1 , and a total of ninety-three vaccine candidates are currently in clinical development 2 . However, the emergence of variants of concern (VOC) of SARS-CoV-2 potentially able to escape pre-existing immunity highlights the need for continuous improvement and adaptation of vaccines 3 4 5 6 7 8 9 . mRNA vaccines represent a promising technology to meet this need: they are based on a highly versatile, adaptable platform technology 10 whose efficacy as a vaccine against SARS-CoV-2 has been demonstrated 11 12 13 14 resulting in authorized vaccines 1 . CureVac's mRNA technology termed RNActive ® 15 16 17 18 is based on non-chemically modified, sequence engineered mRNA. This technology supports high protein expression and moderate activation of innate immune responses 17, 19 . RNActive ® vaccines have shown promise in the context of different infectious diseases in both preclinical 20 19 21 22 and clinical 23 CVnCoV is currently tested in phase 2b/3 studies that investigate the efficacy, safety, and immunogenicity. Here, we show the results of our second-generation SARS-CoV-2 vaccine, CV2CoV. This vaccine was developed to further increase vaccine efficacy, thereby setting the stage to tackle future challenges of the SARS-CoV-2 pandemic. These will likely include the requirement for high vaccine-induced immune responses to compensate for reduced virus neutralisation responses and efficacy against different variants 27 . In addition, emerging immune escape variants might necessitate multivalent vaccines, in which each component needs to be efficacious at a lower dose. Beyond this, dose sparing supported by a more immunogenic vaccine might facilitate providing more doses for a worldwide need. CVnCoV and second generation CV2CoV are sequence optimized, capped, chemically unmodified mRNA-based vaccines that are encapsulated using the same lipid nanoparticle (LNP) technology. Both encode full-length SARS-CoV-2 S protein with pre-fusion stabilising K986P and V987P mutations 28 29 . The vaccines differ in their non-structural elements flanking the open reading frame (ORF), i.e. the 5' and 3' untranslated regions (UTRs) and the 3' tail. These changes were introduced to improve intracellular RNA stability and translation, aimed to increase and prolong protein expression and thereby improve immunogenicity. Here, we show that the optimised mRNA component in CV2CoV indeed supports higher levels of protein expression in cell culture. Vaccination with CV2Cov in a rat model induces robust levels of humoral responses that are detectable upon a single injection and that cross-react with distinct SARS-CoV-2 variants. Despite promising results of CVnCoV in both preclinical models 24 25 and early clinical evaluations 26 In summary, CV2CoV represents a highly promising second-generation vaccine with improved characteristics, including accelerated induction of neutralising antibody titres two weeks after the first vaccination. Its ability to induce high levels of antibodies against SARS-CoV-2 at low doses supports a scenario in which vaccination with CV2CoV allows dose sparing that might be able to contribute to reduce worldwide vaccine shortage. Moreover, this characteristic allows CV2CoV's application in the context of multivalent vaccines that might become necessary as the virus mutates further. Overall, CV2CoV represents a highly promising candidate for further clinical development to help meet some of the challenges of the SARS-CoV-2 pandemic. The mRNA vaccines are based on the RNActive ® platform (claimed and described in e.g. COVID-19 vaccine tracker. 2021. 2. WHO. DRAFT landscape of COVID-19 candidate vaccines Detection of a SARS-CoV-2 variant of concern in South Africa Investigation of novel SARS-COV-2 variant Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 New Vaccine Technologies to Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines A thermostable messenger RNA based vaccine against rabies An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection First proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection Phase 1 Assessment of the Safety and Immunogenicity of an mRNA-Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers SARS-CoV-2 escape mutants and protective immunity from natural infections or immunizations Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera We are very thankful to Thorsten Wolff and to Roman Wölfel for providing SARS-CoV-2 isolates.Thanks to Jennifer Oduro and Jonas Fuener (preclinics mbH) for conducting the study, their outstanding work, commitment and expertise. Special thanks to Prof. Emanuele Montomoli, GiuliaLapini and the Vismederi team for performing excellent work on virus neutralizing antibody assays.